For many patients, injectable therapy has been an effective option, yet acceptance and long-term adherence can be limited by concerns related to injections
Research on Liraglutide has shown an average weight loss of around 5% to 10% of body weight over several months, when used with diet and exercise
10.1007/s00198-018-4649-8 Summary Keywords glucagon-like peptide-1, diabetes mellitus, glucagon-like peptide 1 receptor agonists, osteoporosis, bone resorption Citation Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, Zhang Y and Ding S (2021) The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
"Additional monitoring of kidney function may be needed when starting, or increasing, doses of GLP-1 medications." Kidney Care UK The frequency of follow-up tests should match the patients CKD stage and individual risks
Animal studies suggested potential pancreatic ductal proliferation and inflammation, but these findings have not been consistently replicated in human tissue studies
Alcohol can contribute to weight gain because it is full of excess, empty calories
